Scalper1 News
Drugmaker Actavis (ACT) beat analysts’ Q4 estimates on both the top and bottom lines Thursday, and affirmed its 2014 guidance pending the completion of its buyout of Forest Laboratories (FRX). The stock was up 3% in morning trading on the stock market today and touched an all-time high for the third straight day, above 218. The stock is extended after a 166.42 breakout in early December from a three-weeks tight pattern and ranks No. 8 on the Scalper1 News
Scalper1 News